RicercaInizia una nuova ricerca
NOTA: è possibile cercare una corrispondenza esatta usando i doppi apici, ad es: "evoluzione della specie". Qualora si cerchi un identificativo, è consigliabile cercarlo in due modi differenti: tra apici con caratteri speciali es: "978-94-6366-274" oppure senza caratteri speciali solo come sequenza numerica: es 978946366274.
Primary treatment strategy in elderly patients with hormone receptor positive early breast cancer: is breast cancer surgery.
2020 Nasso, C.; Barbolini, M.; Isca, C.; D'Onofrio, R.; Cortesi, G.; Dominici, M.; Piacentini, F.; Omarini, C.
PROGNOSIS AND RESPONSE TO NEOADJUVANT CHEMOTHERAPY ACCORDING TO HER2 EXPRESSION IN EARLY BREAST CANCER: a retrospective single institution analysis
2020 D'Onofrio, R.; Omarini, C.; Barbolini, M.; Nasso, C.; Isca, C.; Dominici, M.; Piacentini, F.
Prognostic impact of estrogen receptor (ER) level changes during progression for patients with both ER-positive (ER+) primary breast cancer and paired recurrence
2013 Dieci, Maria Vittoria; Barbieri, Elena; Aicha, Goubar; Andre, Fabrice; Omarini, Claudia; Bettelli, Stefania Raffaella; Piacentini, Federico; Guido, Ficarra; Pier, Franco Conte; Guarneri, Valentina
Prognostic significance of germline BRCA mutations in patients with HER2-positive breast cancer. Epidemiological analysis in primary BRCA screens
2021 Viansone, Alessandro; Omarini, Claudia; Boggiani, Daniela; Sikokis, Angelica; Uliana, Vera; Pellegrino, Benedetta; Piacentini, Federico; Michiara, Maria; Musolino, Antonino
Randomized phase II trial of afatinib alone or with vinorelbine versus investigator's choice of treatment in patients with HER2-positive breast cancer with progressive brain metastases after trastuzumab and/or lapatinib-based therapy: LUX-BREAST 3
2014 Piacentini, Federico
STRATEGIES TO PREDICT TREATMENT RESPONSE AND SELECT THERAPIES IN METASTATIC BREAST CANCER PATIENTS USING A NEXT GENERATION SEQUENCING (NGS) MULTI-GENE PANEL
2016 Toss, Angela; Cortesi, Laura; Artuso, Lucia; Tenedini, Elena; Bernardis, Isabella; Parenti, Sandra; Ficarra, Guido; Piacentini, Federico; Federico, Massimo; Tagliafico, Enrico
Survival analysis of the prospective randomized Cher-Lob study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer (BC).
2020 Guarneri, Valentina; Dieci, Maria Vittoria; Bisagni, Giancarlo; Giulio Generali, Daniele; Cagossi, Katia; Sarti, Samanta; Frassoldati, Antonio; Gianni, Lorenzo; Cavanna, Luigi; Pinotti, Graziella; Musolino, Antonino; Piacentini, Federico; Michelotti, Andrea; Cinieri, Saverio; Griguolo, Gaia; Miglietta, Federica; Luca De Salvo, Gian; Franco Conte, Pier
Tumor infiltrating lymphocytes and correlation with pCR in ther CHERLOB study
2014 Piacentini, Federico
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Primary treatment strategy in elderly patients with hormone receptor positive early breast cancer: is breast cancer surgery. | 1-gen-2020 | Nasso, C.; Barbolini, M.; Isca, C.; D'Onofrio, R.; Cortesi, G.; Dominici, M.; Piacentini, F.; Omarini, C. | |
| PROGNOSIS AND RESPONSE TO NEOADJUVANT CHEMOTHERAPY ACCORDING TO HER2 EXPRESSION IN EARLY BREAST CANCER: a retrospective single institution analysis | 1-gen-2020 | D'Onofrio, R.; Omarini, C.; Barbolini, M.; Nasso, C.; Isca, C.; Dominici, M.; Piacentini, F. | |
| Prognostic impact of estrogen receptor (ER) level changes during progression for patients with both ER-positive (ER+) primary breast cancer and paired recurrence | 1-gen-2013 | Dieci, Maria Vittoria; Barbieri, Elena; Aicha, Goubar; Andre, Fabrice; Omarini, Claudia; Bettelli, Stefania Raffaella; Piacentini, Federico; Guido, Ficarra; Pier, Franco Conte; Guarneri, Valentina | |
| Prognostic significance of germline BRCA mutations in patients with HER2-positive breast cancer. Epidemiological analysis in primary BRCA screens | 1-gen-2021 | Viansone, Alessandro; Omarini, Claudia; Boggiani, Daniela; Sikokis, Angelica; Uliana, Vera; Pellegrino, Benedetta; Piacentini, Federico; Michiara, Maria; Musolino, Antonino | |
| Randomized phase II trial of afatinib alone or with vinorelbine versus investigator's choice of treatment in patients with HER2-positive breast cancer with progressive brain metastases after trastuzumab and/or lapatinib-based therapy: LUX-BREAST 3 | 1-gen-2014 | Piacentini, Federico | |
| STRATEGIES TO PREDICT TREATMENT RESPONSE AND SELECT THERAPIES IN METASTATIC BREAST CANCER PATIENTS USING A NEXT GENERATION SEQUENCING (NGS) MULTI-GENE PANEL | 1-gen-2016 | Toss, Angela; Cortesi, Laura; Artuso, Lucia; Tenedini, Elena; Bernardis, Isabella; Parenti, Sandra; Ficarra, Guido; Piacentini, Federico; Federico, Massimo; Tagliafico, Enrico | |
| Survival analysis of the prospective randomized Cher-Lob study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer (BC). | 1-gen-2020 | Guarneri, Valentina; Dieci, Maria Vittoria; Bisagni, Giancarlo; Giulio Generali, Daniele; Cagossi, Katia; Sarti, Samanta; Frassoldati, Antonio; Gianni, Lorenzo; Cavanna, Luigi; Pinotti, Graziella; Musolino, Antonino; Piacentini, Federico; Michelotti, Andrea; Cinieri, Saverio; Griguolo, Gaia; Miglietta, Federica; Luca De Salvo, Gian; Franco Conte, Pier | |
| Tumor infiltrating lymphocytes and correlation with pCR in ther CHERLOB study | 1-gen-2014 | Piacentini, Federico |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile
Opzioni
Scopri
Tipologia
- Atti di CONVEGNO 28
- Atti di CONVEGNO::Poster 28
Data di pubblicazione
- 2020 - 2022 8
- 2010 - 2019 19
- 2007 - 2009 1
Editore
- AMER ASSOC CANCER RESEARCH, 615 C... 1
- Carmine Pinto 1
Rivista
- CANCER RESEARCH 2
- ANNALS OF ONCOLOGY 1
Keyword
- Breast cancer 2
- HER2 positive metastatic breast c... 1
Lingua
- eng 27
Accesso al fulltext
- open 21
- no fulltext 6
- partially open 1